Skip to content

Pharma & Finance Consulting

Active Private limited companyfounded 2022active for 4 yearsPastoor Mensaertstraat 45, 2340 BeerseKBO/BCE: BE 0791.674.606

Lifetime

3 annual accounts with figures on one time axis
peak of €32,685 in 2023
€14,707▼ 21.7%
peak of €18,093 in 2023
€6,378▼ 31.6%
peak of €33,385 in 2025
€33,385▲ 23.6%
€8,799▼ 48.0%
Board1 name since 2022
1 director
Documentsfilings and deeds
30-06-202631 days before the deadline
2025micro format
Gross margin from €18,773 to €14,707Result from €9,330 to €6,378Equity from €27,007 to €33,385Debts from €16,920 to €8,799Cash from €12,839 to €35,011

Key points

from the 2025 annual accounts

Equity

€33,385 ▲ 23.6%

Pharma & Finance Consulting has made a profit in every financial year since 2023.

Turnover

≈ €66,000 estimated

The micro format states no turnover.

Liquidity

3.98 was 2.02 in 2024

Short-term debts fell from €16,085 to €8,799.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,332 companies had the same profile as Pharma & Finance Consulting has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,332 companies, not a prediction for Pharma & Finance Consulting. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • founderdeed of 04-10-2022
Board & ownership

Recent changes

Incorporation Founding capital of €2,500 · Founded by · appointed as director · published on 04-10-2022 · Gazette deed
First establishment Pastoor Mensaertstraat 45, Beerse
All 6 events

Comparable companies

same main activity, similar in size and age
Company
Pharma & Finance Consulting Beerse €42,184 €14,707 79.1% -
R.E.L. Sabbe Antwerp €42,702 €13,305 78.7% -
Guía for Growth Antwerp €37,081 €14,869 55.4% -
Enthuse Kapellen €40,877 €16,971 50.5% -
BluePeak Consult Antwerp €43,454 €13,895 54.1% -
SPCC Putte €43,215 €13,324 54.6% -
JeBo Management Edegem €37,133 €16,832 59.5% -

These companies have the same main activity as Pharma & Finance Consulting: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €37,100 and €43,500, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 30-09-2022Normal situation
Activity
Business and other management consultancyNACE 70200and 5 others
Establishment unit
2.336.358.2322340 Beerse, since 30-09-2022
Financial year end
31 December
Peppol
Reachable via Peppol
Company details

Annual accounts 2025

€42,184▼ 4.0%
Filing
Filed on 30-06-2026, 31 days before the end of the filing period
Financials

Insights on Pharma & Finance Consulting

Pharma & Finance Consulting files the micro format. That format states no turnover. The gross margin fell from €32,685 in 2023 to €14,707 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Pharma & Finance Consulting

What is the company number of Pharma & Finance Consulting?
The company number of Pharma & Finance Consulting is 0791.674.606. The VAT number is the same number with BE in front: BE 0791.674.606.
Where is Pharma & Finance Consulting based?
The registered office is at Pastoor Mensaertstraat 45, 2340 Beerse.Company details
What does Pharma & Finance Consulting do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of Pharma & Finance Consulting?
Pharma & Finance Consulting is a private limited company (BV).
When was Pharma & Finance Consulting founded?
Pharma & Finance Consulting was founded on 30-09-2022.
Is Pharma & Finance Consulting still active?
Yes, Pharma & Finance Consulting is an active enterprise in the KBO register.
What is the turnover of Pharma & Finance Consulting?
The turnover in financial year 2025 is about €66,000. This figure is estimated from the gross margin of €14,707 and 257 comparable companies (NACE 70200). It probably lies between €29,000 and €130,000. It is a rough estimate.Financials
Is Pharma & Finance Consulting profitable?
In financial year 2025, Pharma & Finance Consulting made a profit of €6,378.
Where can I find the annual accounts of Pharma & Finance Consulting?
Pharma & Finance Consulting filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Pharma & Finance Consulting due?
Pharma & Finance Consulting must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.